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AUF1/hnRNP D represses expression of VEGF 
in macrophages
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Roy Favaa,b, Peter Morganellia,d, R. Brooks Robeya,e, and Ralph C. Nicholsa,b,d 
aVeterans Administration Research Service, White River Junction, VT 05009; bDepartment of Medicine, Dartmouth 
Medical School, Hanover, NH 03755; cHoward Hughes Medical Institution Fellowship Program, Dartmouth College, 
Hanover, NH 03755; dDepartment of Immunology and Microbiology and eDepartment of Physiology, Dartmouth 
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ABSTRACT Vascular endothelial growth factor (VEGF) is a regulator of vascularization in de-
velopment and is a key growth factor in tissue repair. In disease, VEGF contributes to vascu-
larization of solid tumors and arthritic joints. This study examines the role of the mRNA-
binding protein AUF1/heterogeneous nuclear ribonucleoprotein D (AUF1) in VEGF gene 
expression. We show that overexpression of AUF1 in mouse macrophage-like RAW-264.7 
cells suppresses endogenous VEGF protein levels. To study 3′ untranslated region (UTR)–
mediated regulation, we introduced the 3′ UTR of VEGF mRNA into a luciferase reporter 
gene. Coexpression of AUF1 represses VEGF-3′ UTR reporter expression in RAW-264.7 cells 
and in mouse bone marrow–derived macrophages. The C-terminus of AUF1 contains argin-
ine–glycine–glycine (RGG) repeat motifs that are dimethylated. Deletion of the RGG domain 
of AUF1 eliminated the repressive effects of AUF1. Surprisingly, expression of an AUF1-RGG 
peptide reduced endogenous VEGF protein levels and repressed VEGF-3′ UTR reporter activ-
ity in RAW-264.7 cells. These findings demonstrate that AUF1 regulates VEGF expression, 
and this study identifies an RGG peptide that suppresses VEGF gene expression.
INTRODUCTION
Vascular endothelial growth factor (VEGF) is a growth factor critical 
for blood vessel growth (Ferrara, 2004). In addition, VEGF acts as a 
cytokine that stimulates immune cells (Ferrara, 2004) and increases 
vascular permeability (Fava et al., 1994). In development, VEGF is so 
critical to blood vessel formation that deletion of one VEGF allele in 
mice results in embryonic lethality (Ferrara, 2004). In adults, VEGF 
acts in a limited and temporal way in processes that require the 
formation of new tissue, such as wound healing (Bao et al., 2009), 
the proliferative stage of the menstrual cycle (Critchley et al., 2001), 
and bone repair (Holstein et al., 2011). In disease, neovasculariza-
tion is key to the growth of solid tumors (Ferrara, 2004), loss of sight 
in intraocular vascularization (Ferrara, 2004), and nourishing of in-
flamed tissue, including the arthritic joint (Paleolog, 2009) and ath-
erosclerotic plaques (Salomonsson et al., 2002). Therapeutic treat-
ments with VEGF to induce angiogenesis are being studied (Ferrara, 
2004), as are therapies that block VEGF protein or VEGF receptors, 
primarily in solid cancers (Ferrara, 2004).
In addition to modulating blood vessel growth, therapies target-
ing VEGF also affect activation of immune cells that bear VEGF re-
ceptors. The macrophage is a central mediator of the innate im-
mune response and plays a critical role in inflammatory processes 
(Gordon, 2007; Paleolog, 2009). Recent studies show that the mac-
rophage combines the innate immune response (activation of Toll 
receptors by bacteria/lipopolysaccharide [LPS]) with the adaptive 
immune response (Fc-receptor recognition of immune complexes; 
Rittirsch et al., 2009). VEGF activates a family of cellular receptors 
(Hiratsuka et al., 2001). Acting as a cytokine, VEGF facilitates mac-
rophage infiltration into inflamed sites (Fava et al., 1994). In blood 
vessel growth, VEGFR-2 is the key receptor and is found on 
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AUF1 and, after 4 h, treated with LPS (50 ng/ml) for 18 h. As shown 
in Figure 1, immunoblotting of VEGF protein levels shows that AUF1 
decreased VEGF modestly (22%) but significantly. This result is es-
pecially interesting since not all cells are transfected successfully by 
transient transfection.
The 3′ UTR region of VEGF represses reporter gene activity
To evaluate the role of the 3′ UTR of VEGF mRNA in gene expres-
sion, we created a luciferase reporter construct (Du et al., 2006). The 
3′ UTR of VEGF mRNA destabilizes mRNA, and when the 3′ UTR of 
VEGF mRNA is introduced into the 3′ UTR of a heterologous re-
porter gene, the reporter activity decreases in resting macrophages 
(Du et al., 2006; Ray and Fox, 2007). When cells are activated, re-
porters with the VEGF-3′ UTR have increased activity (Du et al., 
2006; Ray and Fox, 2007). As shown in Figure 2, introducing the 3′ 
UTR of VEGF into the 3′ UTR of the parental firefly luciferase re-
porter (3.1-Luc) to create the VEGF-3′ UTR-Luc reporter decreased 
gene activity in many cell types (Figure 2). The VEGF-3′ UTR de-
creased reporter activity in RAW-264.7 macrophage cells (60% de-
crease; Figure 2A), as previously reported (Du et al., 2006). The 
VEGF-3′ UTR also decreased reporter activity in mouse primary 
bone marrow–derived macrophages (BMDMs; 50% decrease; Fig-
ure 2B). The VEGF mRNA is regulated posttranscriptionally in the rat 
kidney cell (Feliers et al., 2005), and the VEGF-3′ UTR reduced re-
porter activity in the rat kidney cell line NRK-52E by 80% (Figure 2C). 
The reporter also showed reduced activity in the human embryonic 
kidney (HEK-293) cell line (70% decrease; Figure 2D).
AUF1 decreases the activity of the VEGF-3′ UTR reporter
To determine whether AUF1 affects VEGF-3′ UTR–dependent ex-
pression, we cotransfected AUF1 in RAW-264.7 cells with the VEGF-
3′ UTR-Luc reporter. As shown in Figure 3A, overexpression of AUF1 
decreased luciferase reporter activity by 45%. The mRNA of AUF1 is 
alternatively spliced to produce four isoforms. The smaller isoforms 
(p37 and p40) are more predominant in the cytoplasm and are likely 
more important in regulation of mRNA stability (He and Schneider, 
2006). Overexpression of the p40 isoform also reduced VEGF-3′ 
UTR-Luc activity (45% decrease; Figure 3B). Overexpression of AUF1 
did not affect the activity of the parental reporter, 3.1-Luc (Supple-
mental Table S1).
AUF1 associates with VEGF mRNA
To determine whether AUF1 associates with VEGF mRNA in RAW-
264.7 cells, we immunoprecipitated AUF1 from RAW-264.7 cell 
lysates and measured VEGF mRNA in the pulldown. The presence 
endothelial cells (Hiratsuka et al., 2001). Another receptor, VEGFR-1, 
is also found on endothelial cells but is considered a decoy receptor 
that down-regulates VEGF activity (Hiratsuka et al., 2001). The rela-
tionship between VEGF and macrophage activation has not been 
explored in depth, in part because the macrophage expresses the 
VEGFR-1 receptor (Flt-1) but not VEGFR-2 (Flk-1; Hiratsuka et al., 
2001). For these reasons, the role of VEGF activation of macrophages 
must be seen not simply with respect to blood vessel growth, but 
also in terms of a cytokine promoting macrophage entry into tissue 
(vascular permeability) and activating macrophages through 
VEGFR-1, perhaps by an autocrine mechanism.
Posttranscriptional regulation of gene expression is controlled by 
sequence elements in mRNA and by mRNA-binding proteins that 
recognize mRNA sequence elements. The mRNA regulatory protein 
HuR controls VEGF translation by stabilizing VEGF mRNA (Goldberg-
Cohen et al., 2002). In contrast, AUF1/heterogeneous nuclear ribo-
nucleoprotein (hnRNP) D (AUF1) regulates many mRNAs by destabi-
lizing mRNA, although stabilization of mRNA has also been reported 
(Kiledjian et al., 1997; Sela-Brown et al., 2000). Genetic deletion of 
AUF1 in the mouse results in multiple disease phenotypes, includ-
ing endotoxic shock (Lu et al., 2006), pruritic inflammatory skin dis-
ease (Sadri and Schneider, 2009), and B cell dysfunction (Sadri et al., 
2010). However, the effect of AUF1 on VEGF gene expression has 
not been studied. Translational regulation of VEGF gene expression 
by other mRNA-regulatory proteins has been the subject of recent 
review (Yoo et al., 2006), and adenosine-uridine–rich elements 
(AUREs) have been characterized (Chen and Shyu, 1995; Xu et al., 
1997; Ray and Fox, 2007). Genetic separation of the VEGF 3′ un-
translated region (UTR) from the coding region by insertion of a re-
porter gene resulted in embryonic lethality in mice, demonstrating 
the importance of the 3′ UTR in regulating VEGF gene expression 
(Miquerol et al., 2000). We previously identified a region of VEGF 3′ 
UTR that contains an AURE, and we hypothesized that the AU-rich 
element affected gene expression (Du et al., 2006). We identified a 
similar AU-rich region in the 3′ UTR of glucose transporter-1 (GLUT1) 
mRNA (Griffin et al., 2004). A recent report shows that the AU-rich 
element in human VEGF mRNA regulates gene expression by alter-
nating secondary structures of RNA (Ray and Fox, 2007). These facts 
led us to investigate the role of regulatory mRNA-binding proteins 
that control translation of VEGF mRNA in macrophages.
This study evaluates the effects of AUF1 on expression of endog-
enous VEGF protein and VEGF 3′ UTR–dependent reporters. We 
are the first to show that AUF1 affects endogenous VEGF protein 
levels and VEGF-3′ UTR–dependent gene expression. To investigate 
the mechanism of AUF1 action and identify novel regulators of 
VEGF gene expression, we focus on a regulatory region of the AUF1 
protein. The C-terminal region contains multiple arginine–glycine–
glycine (RGG) motifs in an RGG domain. The arginine residue in the 
third RGG motif is enzymatically methylated on the guanidinium 
side chain (Ong et al., 2004). The effects of blockade of arginine 
methylation are examined. Finally, we design peptides modeled on 
the AUF1 RGG domain and measure the effects on endogenous 
VEGF protein levels and VEGF-3′ UTR–dependent reporter activity. 
The identification of rationally designed peptide regulators of AUF1 
may yield novel methods to repress VEGF gene expression.
RESULTS
AUF1 decreases VEGF protein levels
To determine whether the mRNA-binding protein AUF1 affects en-
dogenous VEGF protein production, we cloned the p37 isoform of 
human AUF1 into the pcDNA-3.1-V5-His expression construct. 
Cultured RAW-264.7 macrophage-like cells were transfected with 
FIGURE 1: Effects of overexpressing AUF1 on endogenous VEGF 
protein levels. Cultured RAW-264.7 cells were grown to 50% 
confluence and transfected with full-length AUF1 (AUF1) or the empty 
parental vector pcDNA-3.1 (PC). After 4 h, cells were treated with LPS 
for 18 h. Lysates were probed for VEGF and α-tubulin. Two of six 
experiments are shown. For six experiments, VEGF protein 
(normalized to α-tubulin) was decreased by 22% (p < 0.04).
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protein in macrophages, and future studies will 
determine whether AUF1 interacts directly with 
the VEGF mRNA.
Sequence homology of AUF1
To identify functional domains of AUF1, several 
studies have used sequence analysis (DeMaria 
et al., 1997; He and Schneider, 2006). To ex-
tend these studies, we identified regions of 
AUF1-p37 that are homologous to other spe-
cies. Homology analysis was performed using 
BLAST (National Center for Biotechnology In-
formation) and is shown in Figure 5A. Different 
homologies were found for three regions, en-
coded by exons 1, 3–5, and 6 and 8. The AUF1-
p37 isoform lacks exons 2 and 7 (Figure 5B). As 
shown in Figure 5B, the central region of AUF1 
contains two RNA recognition motifs (RRMs) 
that are highly conserved (Figure 5A). The C-
terminal region, encoded by exons 6 and 8, is 
also conserved, except for opossum and panda 
(Figure 5A). The N-terminus shows many non-
identical residues between species (Figure 5A), 
with the most variation occurring in serine and 
threonine residues. Studies have shown that 
the N- and C-terminal regions contribute to, 
but are not primarily involved in, RNA binding 
(DeMaria et al., 1997). The N- and C-terminal 
regions are both candidate regulatory regions 
(DeMaria et al., 1997; He and Schenider, 2006), 
and the role of the C-terminus in AUF1 function 
is the subject of this study. The amino acid 
sequences of AUF1-p37 and other AUF1 regions are shown in 
Figure 5C.
C-Terminal RGG motifs
Many regulatory mRNA-binding proteins shuttle between the cyto-
plasm and nucleus, and localization to the cytoplasm increases ef-
fects on regulated mRNA (He and Schenider, 2006). The RGG repeat 
protein motif affects cytoplasmic localization of another mRNA-
binding protein, hnRNP A2 (Nichols et al., 2000). Arginine residues 
in RGG motifs of hnRNP A2 are methylated, and blockade of methy-
lation with adenosine dialdehyde (AdOx) eliminated preferential 
nuclear localization of hnRNP A2 (Nichols et al., 2000). The RGG 
domain in AUF1-p37 includes three RGG motifs within a 27–amino 
acid (aa) sequence (Figure 5B), and the arginine in the third RGG 
motif of AUF1 is dimethylated (Ong et al., 
2004). Treatment of several cell types with 
AdOx did not affect cytoplasmic/nuclear local-
ization of AUF1 (He and Schenider, 2006). How-
ever, AdOx treatment of RAW-264.7 cells af-
fects AUF1 protein levels (see later discussion).
Deletion of N- or C-terminal region 
affects AUF1 activity
Previous studies showed that N- and C-termi-
nal regions are required for maximal RNA bind-
ing (DeMaria et al., 1997). To determine 
whether the N- and C-terminal regions are nec-
essary for regulating VEGF gene expression in 
RAW-264.7 cells, we deleted portions of the N- 
and C-termini from AUF1. The RGG domain 
of AUF1 isoforms in the pulldown was confirmed by immunoblot-
ting (Figure 4A). AUF1 has been reported to act on multiple genes 
(Mazan-Mamczarz et al., 2009), and PCR was performed to identify 
other AURE-containing mRNAs pulled down with AUF1. As shown 
in Figure 4B, PCR products for VEGF, GLUT1, and hexokinase-2 
(HK2) could be amplified from cDNA prepared from anti-AUF1 pull-
downs. Pulldowns without and with anti-AUF1 antibody contained 
the very abundant 18S RNA (Figure 4B). Beads alone (no anti-AUF1 
antibody added) and pulldowns with sera (mouse, rat, goat, bovine) 
brought down no VEGF mRNA. For comparison of VEGF mRNA as-
sociated with AUF1, we performed parallel pulldowns with a control 
antibody (anti-Tie2). By real-time PCR analysis, there was 3.6-fold-
greater VEGF mRNA associated with AUF1 than with the control. 
This result demonstrates that VEGF mRNA associates with AUF1 
FIGURE 2: Effects of the 3′ UTR of VEGF mRNA on reporter activity in multiple cell types. 
(A) VEGF-3′ UTR-luciferase (VEGF-3′ UTR-Luc) or the empty parental vector (3.1-Luc) were 
transfected into RAW-264.7 cells using Lipofectamine 2000. Luciferase activity was measured 
in cell lysates. (B) Bone marrow–derived macrophages were obtained from C57/Bl6 mouse 
femurs and cultured in L-400 media. After 6 d, cells were trypsinized and transfected with 
VEGF-3′ UTR-Luc or 3.1-Luc by electroporation (Amaxa). (C) Normal rat kidney cells 
(NRK-52E) were cultured for <30 passages and transfected with VEGF-3′ UTR-Luc or 3.1-Luc 
using Lipofectamine 2000. (D) HEK-293 cells were transfected with VEGF-3′ UTR-Luc or 
3.1-Luc using Lipofectamine 2000. All transfections (A–D) were incubated for 18–24 h before 
cell lysis. Results are normalized to 3.1-Luc transfection, and are representative of two or 
more experiments. Shown are mean and SD. p < 0.001 for A and C. p < 0.01 for B and D.
FIGURE 3: Effects of overexpressing AUF1 on VEGF-3′ UTR-luciferase. Cultured RAW-264.7 
cells were cotransfected with VEGF-3′ UTR-Luc and either AUF1-p37 (A) or AUF1-p40 (B). 
After 24 h, cells were lysed and luciferase activity measured. Results are normalized to 
transfection with pcDNA-3.1 and are representative of two or more experiments. Shown are 
mean and SD. p < 0.001 for A and p < 0.0001 for B.
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tein degradation can be measured. As shown in Figure 8, although 
with CYX treatment the double deletant appeared to have more 
rapid decay than the wild-type AUF1, the difference was not signifi-
cantly different (Figure 8). Hence the two deletants with reduced 
protein levels (AUF1-Δ21-Ala and AUF1-Δ21-Ala+ΔQRGG; Figure 7) 
displayed decay similar as wild type. More studies are needed to 
explain why the AUF1-Δ21-Ala and AUF1-Δ21-Ala+ΔQRGG dele-
tant proteins are expressed at lower levels. To summarize these pro-
tein studies: 1) the loss of activity on VEGF reporters by deletants 
lacking the N-terminal polyalanine region (Figure 6B) likely results 
from reduced protein levels (by an unknown mechanism); and 2) loss 
of activity on VEGF reporters by the AUF1-ΔQRGG C-terminal dele-
tant (Figure 6A) does not result from reduced levels of the deletant 
protein.
Blockade of arginine methylation reduces AUF1 protein
To extend our analysis of the C-terminal regulatory region, we 
next determined whether methylation of arginine residues affects 
protein levels. Cultured RAW-264.7 cells were treated with an 
arginine methylation inhibitor, AdOx, for 48 h. Both endogenous 
AUF1 (Figure 9A) and AUF1-V5 (Figure 9B) protein levels were 
decreased with AdOx treatment. However, the AUF1-ΔQRGG 
mutant was less affected by AdOx treatment (Figure 9B). Hence 
deletion of the QRGG region did not affect protein levels (Figure 
7), but blockade of arginine methylation decreased AUF1 protein 
levels by a mechanism that is not clear. Together these results 
suggest that deletion of the QRGG motif is a functional deletion 
and that arginine methylation is important to AUF1 protein 
levels.
Effects of AUF1-RGG peptides on VEGF gene expression
The reported functions of the RGG domain in the C-terminal re-
gion include homodimer formation (Kajita et al., 1995), RNA bind-
ing (Raman et al., 2001), and protein–protein interaction with 
regulatory proteins (Raman et al., 2001; He and Schneider, 2006). 
We hypothesized that a peptide modeled on the C-terminus 
might interfere with binding of AUF1 with its binding partners and 
act as a dominant-negative peptide. Two AUF1-RGG peptides 
were created in expression vectors. One peptide contains the re-
gion encoded by exons 6 and 8 (AUF1-Ex6+8; Figure 5B). The 
second is a shorter peptide whose N-terminus begins at the poly-
glutamine sequence (AUF1-QRGG; Figure 5B). As shown earlier 
(Figure 1), treatment of RAW-264.7 cells with full-length AUF1 de-
creased endogenous VEGF protein levels. To determine whether 
expression of the RGG peptides affects endogenous VEGF ex-
pression, RAW-264.7 cells were transfected with the empty vector 
(PC), the AUF1-QRGG peptide (QRGG), or the AUF1-Ex6+8 pep-
tide (6+8). As shown in Figure 10, A and B, endogenous VEGF 
levels were decreased by 35% (AUF1-Ex6+8) or 40% (AUF1-
QRGG). To determine whether the AUF1-RGG peptides affect ex-
pression of the VEGF-3′ UTR reporter, we cotransfected RAW-
264.7 cells with VEGF-3′ UTR-Luc together with AUF1-6+8 or 
AUF1-QRGG. The amount of repression of reporter activity was 
the same with AUF1-RGG peptides and full-length AUF1 (Figure 
10C). As a negative control, a small scrambled peptide did not 
affect reporter activity when compared with overexpressed AUF1 
(Supplemental Figure S4). Hence peptides modeled on the RGG 
domain of AUF1 are effective inhibitors of endogenous VEGF 
gene expression and likely act by a 3′ UTR–mediated mechanism. 
Future studies will identify the active motif in AUF1-RGG peptides 
and further characterize the mechanism by which AUF1-RGG pep-
tides repress VEGF gene expression.
and a nearby polyglutamine region (poly-Q) contribute to RNA 
binding (DeMaria et al., 1997) and were removed (Figure 5B). The 
AUF1-ΔQRGG mutant was expressed in RAW-264.7 cells and 
showed a loss of the inhibitory effect on VEGF-3′ UTR-Luc reporter 
activity (Figure 6A). Deletion of 21 aa in the N-terminal region within 
an alanine-rich region (AUF1-Δ21-Ala; Figure 5B) also eliminated the 
inhibitory effects on VEGF reporter (Figure 6B), as did a double de-
letant (AUF1-Δ21-Ala+ΔQRGG; Figure 6B). Deletions may reduce 
affects on reporter activity by reducing deletant protein levels, and 
protein levels of AUF1 deletants were measured next.
Effects of deletions on AUF1 protein levels
To determine whether N- or C-terminal deletions affect protein lev-
els, full-length AUF1 or AUF1 deletants were expressed in RAW-
264.7 cells and immunoblotted with anti-V5 antibody. Deletion of 
21 amino acids from the polyalanine region decreased AUF1 pro-
tein levels (Figure 7). However, protein levels of the AUF1-ΔQRGG 
mutant were similar to those of full-length AUF1 (Figure 7). The 
double deletant (AUF1-Δ21-Ala+ΔQRGG) was expressed at lower 
levels, similar to the AUF1-Δ21-Ala deletant (Figure 7). Larger dele-
tions of the polyalanine region (up to 34 aa) also reduced protein 
levels (Supplemental Figure S1).
Proximal to the polyalanine region are candidate ubiquitination 
sites, and deletion of the polyalanine motifs may affect protein deg-
radation via ubiquitin-mediated proteasomal degradation. To evalu-
ate whether proteasomal inhibition affected AUF1 or AUF1 dele-
tants, cells were transfected and then treated with MG132. 
Proteasomal inhibition increased endogenous AUF1-V5 levels (Sup-
plemental Figure S2A). Protein levels of both the AUF1-Δ21-Ala de-
letant and the AUF1-ΔQRGG also increased with MG132, but the 
increases were less (Supplemental Figure S2A). The double deletant 
(AUF1-Δ21+ΔQRGG) was not affected by MG132 (Supplemental 
Figure S2B), suggesting that both N- and C-terminal regions affect 
proteasomal degradation of AUF1.
To determine whether decreased protein levels resulted from re-
duced transfection efficiency, in separate experiments, we cotrans-
fected AUF1 or AUF1 deletants with a parental luciferase vector 
(Renilla luciferase). The transfection efficiency of all constructs was 
the same (Supplemental Figure S3). Finally, to evaluate whether the 
protein levels result from changes in protein turnover, we performed 
cycloheximide (CYX) inhibition studies (50 μg/ml for 0, 1, or 4 h). 
Treatment with CYX inhibits protein translation, and the rate of pro-
FIGURE 4: Immunoprecipitation of mRNA associated with AUF1. (A) 
AUF1 protein was isolated with anti-AUF1 antibody and protein A 
beads and the pulldown analyzed for AUF1 protein. Control 
pulldowns were performed with no anti-AUF1 antibody (No Ab). (B) 
To identify mRNA associated with AUF1, RNA was purified from 
pulldown beads and the cDNA amplified for VEGF, GLUT1, HK2, or 
18S RNA. PCR products are shown.
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DISCUSSION
Vascular endothelial growth factor is critical 
as a growth factor in blood vessel growth 
and as a cytokine in immune cell activation 
(Ferrara, 2004). Our studies (Du et al., 2006) 
and the studies of others (De Bandt et al., 
2003) demonstrate that VEGF acts as a cy-
tokine in macrophages, activating the cell 
through VEGFR-1 (De Bandt et al., 2003). 
Hence macrophages both respond to and 
produce VEGF. In human disease, mac-
rophage cells may exacerbate disease when 
overactivated or may play a role in fighting 
disease when killing bacteria or as tumor-
infiltrating macrophages (Gordon, 2007; 
Stockmann et al., 2008). Growth factor stim-
ulation of macrophages leads to increased 
VEGF gene transcription (Jiang and Liu, 
2009) and stabilization of VEGF mRNA (Du 
et al., 2006). This study demonstrates that 
the mRNA-binding protein AUF1/hnRNP D 
regulates expression of VEGF.
Expression of genes is primarily regu-
lated by transcription acting on gene pro-
moter and enhancer sequences. However, 
genes that encode proteins involved in cell 
activation, such as cytokines and growth fac-
tors, are often regulated posttranscription-
ally (Xu et al., 1997). Posttranscriptional 
regulatory steps include 1) splicing and pro-
cessing, 2) nuclear export, 3) cytoplasmic 
localization, 4) translational efficiency, and 5) 
degradation (Ferrara, 2004). Our previous 
studies show that a region of the 3′ UTR of 
VEGF mRNA that contains an adenosine-
uridine–rich element regulates VEGF gene 
FIGURE 5: (A) Sequence analysis of AUF1. Shown are comparisons of the nine most closely 
related species with human AUF1-p37. Exons 2 and 7 are alternatively spliced out of the p37 
isoform. Vertical lines show single–amino acid variations or single–amino acid gaps as compared 
with human. (B) Diagram showing the 
structure of AUF1, including two polyalanine 
motifs (poly-Ala; 11-AAAAA-15 and 
37-AAAAA-41), two RRMs, a polyglutamine 
stretch (poly-Q; 245-QQQQQ-249), and three 
RGG repeats (253-RGG-255, 263-RGG-265, 
and 277-RGG-279). Alternative splicing that 
retains exon 2, exon 7, or both produces the 
other AUF1 isoforms (AUF1-p40, -p42, -p45; 
not shown). Below are shown AUF1 deletion 
constructs and AUF1-RGG peptides: 
AUF1-Δ21-Ala (aa 13–33 deleted), AUF1-
ΔQRGG (aa 206–280 deleted), AUF1-Ex6+8 
(aa 234–287), and AUF1-QRGG (aa 245–287). 
(C). (i) Amino acid sequence of human 
AUF1-p37. Shown in boldface italic font are 
the polyalanine motifs in exon 1 and the 
polyglutamine and RGG repeat motifs in the 
C-terminal region. G–K denotes the end of 
exon 1. K–C denotes the beginning of exon 
6. (ii) The polyalanine region of AUF1 exon 1. 
The amino acids removed in the AUF1-Δ21-
Ala deletant are underlined. (iii) The region 
deleted in AUF1-ΔQRGG. (iv) The amino acid 
sequence of the AUF1-Ex6+8 (top) and 
AUF1-QRGG (bottom) peptides.
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Regulation by mRNA-binding proteins on 
3′ UTR elements is analyzed by introducing 
the 3′ UTR from regulated mRNA (VEGF, 
GLUT1, tumor necrosis factor-α [TNF]) into 
the 3′ UTR of reporter genes (firefly luciferase 
or green fluorescent protein; Griffin et al., 
2004; Du et al., 2006; Nichols et al., 2010). In 
this study, the 3′ UTR of VEGF was placed in 
the 3′ UTR of a luciferase reporter, as de-
scribed previously (Du et al., 2006). In resting 
macrophages and other cell types, the 3′ 
UTR decreases reporter expression (Figure 2; 
Du et al., 2006). When cells are stimulated, 
reporter expression increases (Du et al., 
2006). This study establishes that AUF1 regu-
lates 3′ UTR–dependent gene expression by 
inhibiting VEGF-3′ UTR–dependent luciferase 
reporter expression in RAW-264.7 cells (Fig-
ure 3). Attempts to knock down AUF1 using 
small inhibitory RNA (siRNA) in RAW-264.7 
and BMDM cells by transient transfection 
was only modestly successful (∼10–30% de-
crease), and although VEGF mRNA and 
VEGF-3′ UTR-Luc activity increased modestly, 
the increase was not significant (unpublished 
data). Future studies will use knockdown-
stable cell lines in which all cells are affected by siRNA.
To understand the mechanism by which AUF1 inhibits VEGF ex-
pression, this study investigates the regulatory regions lying N- and 
C-terminal to the highly conserved RNA-binding domain (Figure 5). 
Deletion of a polyalanine-rich region in the N-terminus reduced ac-
tivity on the VEGF-3′ UTR-Luc reporter (Figure 6B), a result most 
likely due to reduced protein levels (Figure 7). The N-terminus is 
important for protein folding, and loss of N-terminal sequence may 
reduce the level of successfully folded protein (Peroutka et al., 2011). 
The C-terminus of AUF1 contains a region with three repeat RGG 
motifs. Arginine residues in RGG motifs are enzymatically 
expression (Du et al., 2006). Our earlier reports also identified a 
similar AU-rich element in the 3′ UTR of GLUT1 mRNA (Griffin et al., 
2004). Another report showed that the AU-rich element in human 
VEGF mRNA regulates gene expression in macrophages by alter-
nating secondary structures of RNA (Ray and Fox, 2007). In a renal 
cell carcinoma model, Xin et al. (2012) show that AUF1 binds VEGF 
AU-rich elements under both normoxia and hypoxia and that regu-
lation of larger isoforms of AUF1 (p42 and p45) is mediated by a 
VHL-RNP complex. The AU-rich elements in 3′ UTR regions regulate 
gene expression in concert with mRNA-binding proteins (Xu et al., 
1997). We report here that overexpression of the AUF1 mRNA-bind-
ing protein decreases endogenous VEGF protein levels (Figure 1), 
establishing the biological significance of AUF1 action on VEGF 
gene expression. This study investigates posttranscriptional regula-
tion of VEGF mRNA by the AUF1 mRNA-binding protein.
FIGURE 6: Deletion of C- and N-terminal regions reduces activity. (A) The AUF1 or AUF1-
ΔQRGG (dQRGG) expression plasmids were cotransfected into RAW-264.7 cells with VEGF-3′ 
UTR-Luc (see Figure 5B). Data are normalized to cells transfected with the empty expression 
plasmid pcDNA-3.1 (pcDNA). Deletion of the QRGG region inactivated the inhibitory effect of 
AUF1 on VEGF-3′ UTR-Luc. p < 0.0001, pcDNA vs. AUF1; pcDNA vs. ΔQRGG was not 
significantly different. p < 0.0001 AUF1 vs. ΔQRGG. (B) Deletion of 21 aa (AUF1-Δ21-Ala, d21) 
from the polyalanine region of the full-length AUF1 inactivated AUF1. Effects of the double 
deletant (both the polyalanine and the QRGG region deleted) are also shown (d21+dQRGG). 
p < 0.0001, pcDNA vs. AUF1; pcDNA vs. Δ21 was not significantly different; p < 0.03, pcDNA 
vs. Δ21+ΔQRGG; p < 0.0001, AUF1 vs. Δ21; p < 0.0001, AUF1 vs. Δ21+ΔQRGG; p < 0.02, Δ21 
vs. Δ21+ΔQRGG. Results are normalized to transfection with pcDNA and are representative of 
two or more experiments. Shown are mean and SD.
FIGURE 7: Effects of N- and C-terminal deletions on protein levels. 
Lysates of RAW-264.7 cells expressing V5-tagged full-length 
AUF1-p37 (FL) or the polyalanine deletant (AUF1-Δ21; d21) or the 
QRGG deletant (dQ/RGG) were immunoblotted with anti-V5 
antibody. The d21+dQ/RGG deletant lacks both the polyalanine and 
the QRGG regions. Results are representative of three experiments.
FIGURE 8: Effects of cycloheximide inhibition on V5-tagged protein 
synthesis. Cultured RAW-264.7 cells were transfected with the 
full-length AUF1-V5 protein (AUF), the N-terminal deletant AUF1-d21-
Ala (d21-Ala), the C-terminal deletant (dQRGG), or the double 
deletant (d21-Ala+dQRGG). After 24 h, cells were treated with 
cycloheximide for 0, 1, or 4 h. Cell lysates were immunoblotted with 
anti-V5 antibody, and protein levels were normalized to α-tubulin 
levels. Levels of each protein type are expressed relative to untreated 
controls. The change in deletant protein levels was not significantly 
different from AUF1 at any time point. Compared to AUF1, the 
double-deletant protein levels were decreased by 40% after 4 h, but 
the decrease was not significant (p < 0.10). Results are the mean and 
SD for three separate experiments.
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of AUF1 to the nucleus and increases the effects of AUF1 on mRNA 
(He and Schenider, 2006). The 14-3-3σ protein increases cytoplas-
mic levels of AUF1 and would be predicted to decrease VEGF gene 
expression. Interruption of 14-3-3σ by AUF1-RGG peptides would 
reverse the action of 14-3-3σ and increase VEGF gene expression. 
On the basis of our results, it is more likely that the AUF1-RGG pep-
tides promote or mimic the action of 14-3-3σ. There is no apparent 
homology between 14-3-3σ and the AUF1-RGG peptides.
Our results demonstrate that AUF1-RGG peptides derived from 
AUF1 can regulate VEGF gene expression. The most likely mecha-
nism for AUF1-RGG peptide action is binding to AUF1 and increas-
ing AUF1 activity. Alternatively, AUF1-RGG peptides may interact 
with other regulatory proteins that are binding partners of the RGG 
domain of AUF1 (He and Schenider, 2006). Determining how AUF1-
RGG peptides act to change VEGF gene expression in macrophages 
is the focus of ongoing studies. Design of novel biologically active 
AUF1 peptides will identify the binding partner and optimize the 
pharmacokinetics of this reagent, which may be valuable in reduc-
ing VEGF gene expression.
MATERIALS AND METHODS
Reagents
AdOx, LPS, CYX, and MG132 were from Sigma-Aldrich (St. Louis, 
MO).
Cell culture
The RAW-264.7 cell lines were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA) and maintained as 
dimethylated by protein arginine methyltransferase. This posttrans-
lational modification produces many effects on biological activity 
(Bedford and Clarke, 2009; Yu, 2011). Dimethylation of RGG motifs 
alters the structure of RNA to which RGG motifs bind but does not 
affect the affinity of binding (Raman et al. 2001). Blockade of argin-
ine methylation with adenosine dialdehyde decreased AUF1 pro-
tein levels, suggesting a role for methylated arginines in protein 
stability (Figure 9). However, deletion of the RGG domain did not 
affect protein levels (Figure 7). Together these results suggest that 
AdOx produces AUF1 proteins with unmethylated RGG motifs, and 
the unmethylated arginines in RGG motifs mark the protein for de-
cay. Loss of the RGG domain inactivated the repressive effects of 
AUF1 on the VEGF-3′ UTR reporter (Figure 6A), which suggested 
that this region of AUF1 is a candidate for regulatory peptides.
To understand the mechanism of AUF1 action and identify pos-
sible regulatory AUF1-RGG peptides, two C-terminal sequences 
(AUF1-Ex6+8 and AUF1-QRGG) were studied. Expression of these 
AUF1-RGG peptides was anticipated to disrupt protein–protein in-
teractions (DeMaria et al., 1997; He and Schneider, 2006) or inter-
fere with binding of AUF1 to RNA (Raman et al., 2001) and reverse 
the inhibitory effect of AUF1 on VEGF gene expression. Surprisingly, 
AUF1-RGG peptides reduced VEGF-3′ UTR-Luc activity to the same 
degree as full-length AUF1 (Figure 10C). Perhaps more interesting, 
expression of AUF1-RGG peptides also reduced endogenous VEGF 
protein levels (Figure 10, A and B), reductions that were greater than 
found with the full-length AUF1 (Figure 1). A likely mechanism of 
action by AUF1-RGG peptides is inactivation of an inhibitory regula-
tor of AUF1. The 14-3-3σ protein binds to a portion of the RGG 
domain of AUF1-p37 and -p40 but not to the larger isoforms (He 
and Schenider, 2006). The interaction site overlaps with a putative 
nuclear localization signal, and 14-3-3σ appears to block localization 
FIGURE 9: Effects of adenosine dialdehyde on AUF1 protein. 
(A) Cells (RAW-264.7) were treated with AdOx (5 µM) for 48 h, and 
lysates were immunoblotted for AUF1 isoforms. Loading control was 
α-tubulin. (B) The effects of AdOx (5 µM for 48 h) were measured on 
RAW-264.7 cells transfected with AUF1 (WT) or AUF1-ΔQRGG-V5 
(dQRGG). Triplicate samples were immunoblotted with anti-V5 
antibody. WT, dimethyl sulfoxide (DMSO) vs. AdOx, p < 0.0001; 
AUF1-ΔQRGG, DMSO vs. AdOx, p < 0.001. Results are normalized to 
DMSO treatment and are representative of two or more experiments. 
Shown are mean and SD.
FIGURE 10: Effects of AUF1-RGG peptides on endogenous VEGF 
protein levels. Cultured RAW-264.7 cells were transfected with the 
empty parental vector, pcDNA-3.1 (PC), the AUF1-QRGG peptide 
vector (QRGG), or the AUF1-6+8 peptide vector (6+8). After 4 h, cells 
were treated with LPS for 18 h. Lysates were probed for VEGF and 
α-tubulin. (A) Immunoblot for VEGF or α-tubulin. (B) Levels of VEGF 
protein normalized to α-tubulin for six experiments. As compared with 
pcDNA-3.1, both AUF1-QRGG (p < 0.002) and AUF1-6+8 (p < 0.003) 
significantly decreased VEGF protein. (C) Effects of AUF1 peptides on 
VEGF-3′ UTR reporter activity. Cells (RAW-264.7) were transfected 
with VEGF-3′ UTR-Luc and were cotransfected with pcDNA-3.1, AUF1 
(AUF1-p37), or AUF1-RGG peptides (Ex6+8 or QRGG). The luciferase 
activity in cell lysates from triplicate wells was read after 24 h. p < 
0.0001 for pcDNA vs. AUF, AUF1-Ex6+8, or AUF1-QRGG. No other 
comparators were significantly different. Results are normalized to 
pcDNA treatment and are representative of two or more experiments.
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Plus dual-color protein standard (Bio-Rad) was used to determine 
molecular weight. Blots were probed with antibodies to AUF1 
(Millipore, Billerica, MA), V5 (Invitrogen), or Tie2 (Santa Cruz 
Biotechnology, Santa Cruz, CA). Blots were developed with horse-
radish peroxidase (HRP) secondary antibodies (mouse and rabbit 
secondary HRP antibodies were from Sigma-Aldrich) using X-Omat 
film (Kodak, Rochester, NY) or imaged using the VersaDoc system 
(Bio-Rad). Protein levels were quantitated by scanning immunoblots 
or digital images. The image intensities were measured using 
ImageJ (National Institutes of Health, Bethesda, MD). Protein bands 
were normalized to α-tubulin (Sigma-Aldrich).
RNA isolation and real-time PCR
Total cellular RNA was isolated using the QiaShredder columns and 
the RNeasy kit (Qiagen, Valencia, CA). The RNA was quantified using 
a NanoDrop (Thermo Fisher Scientific, Waltham, MA). Next, 1–5 μg 
of RNA was treated with Turbo-DNA-free (Ambion, Austin, TX), and 
cDNA was created using the Maxima First Strand cDNA kit (Fermen-
tas, Glen Burnie, MD). Real-time PCR was performed with RT2 Real 
Time SYBR Master Mix (SABiosciences, Frederick, MD), using stan-
dard conditions. Levels of mRNA (Ct) were normalized to the level of 
18S RNA. All samples were run in triplicate. Melting curves were per-
formed to confirm single PCR products. Primer pairs are as follows. 
Mouse VEGF: sense, aagtgatcaagttcatggatgtcta; antisense, aagct-
catctctcctatgtgctg. Mouse hexokinase 2: sense, aactgagtttgacaga-
gagatcgac; antisense, gtcttcaatatccgagacatctttg. Mouse GLUT1: 
sense, caatgctgtgttctactactcaacg; antisense, gatgctcagataggacatc-
caag. 18S rRNA: sense, gcatatgcttgtctcaaagattaag; antisense, tatt-
agctctagaattaccacagttatcca. Primer pairs cross introns, except the 
18S RNA gene, which lacks introns. To verify the size of PCR prod-
ucts, amplicons were separated on a 2% NuSieve DNA gels, stained 
with Syber Gold (Molecular Probes, Invitrogen), and imaged by 
VersaDoc.
AUF1/mRNA immunoprecipitation
RAW-264.7 cells were plated with 1 × 107 cells in 10-cm plates. The 
next day, the cells were lysed in 1 ml of lysis buffer (LB; 10 mM Tris-
HCl, pH 8.0, 1.5 mM MgCl2, 100 mM NaCl, 0.5% Tween-20, com-
plete protease cocktail [Roche, Indianapolis, IN]) plus RNAse Protect 
(Sigma-Aldrich). Lysate was precleared with 50 μl of equilibrated 
protein A magnetic beads (Millipore). A 20-μg amount of antibody 
to AUF1 or Tie2 (control) was bound to beads. Antibody-bound 
beads were incubated with 300 μg of total cellular protein overnight 
rotating at 4°C. Beads were washed repeatedly with LB, and RNA 
was purified (RNeasy). Levels of mRNA were measured by PCR, fol-
lowed by DNA gel electrophoresis or by real-time PCR.
Plasmid construction
AUF1 expression constructs. Human AUF1-p37 and AUF1-p40 
expression plasmids were created using AUF1 plasmids as template 
(generous gift of Robert Schneider, New York University, New York, 
NY). Coding regions were amplified by PCR and cloned into pcDNA-
3.1-V5-His (Invitrogen). The parental vector control for AUF1 
overexpression experiments was pcDNA-3.1. The polyalanine 
AUF1-p37 deletant (Δ21-Ala; aa 13–33 deleted) was created by low-
stringency (low annealing temperature) whole-plasmid PCR. A 
deletion construct of the C-terminal region of AUF1-p37 (ΔQRGG, 
aa 206–278 deleted) was generated using the PCR-based 
QuikChange Mutagenesis Kit (Stratagene, Santa Clara, CA). The 
ΔQRGG construct retains a hybrid RGG motif at the site of the 
deletion. A double deletant (Δ21-Ala+ΔQRGG) was created by 
using PCR cloning using Δ21-Ala as template. Fragments of AUF1 
previously described (Griffin et al., 2004; Du et al., 2006). Medium 
was low-glucose DMEM supplemented with 10% heat-inactivated 
fetal bovine serum (FBS). HEK-293 cells were obtained from ATCC 
and maintained in DMEM media supplemented with 10% FBS. Cells 
were grown without antibiotics. Cell treatments with LPS, AdOx, or 
CYX are described in the text.
BMDMs were obtained from male C57/Bl6 mice. Cells were col-
lected from femoral shafts by flushing with RPMI-1640 containing 
10% FBS. The cell suspensions were passed through a 21-gauge 
needle in RPMI-1640 to disperse cell clumps and then filtered using 
a 70-μm nylon cell strainer to remove bone fragments. Adherent 
bone marrow cells (stroma and mature macrophages) were removed 
by incubation in tissue culture plates at 37°C overnight. The nonad-
herent bone marrow cells were then cultured in RPMI-1640, 10% 
FBS, 20% L-cell conditioned medium, and gentamicin (50 μg/ml). 
The media was supplemented every 2–3 d, and the macrophages 
were harvested after 7–10 d.
Cell transfection and luciferase assay
For transfection studies, cultured cells were plated ∼24 h prior to 
transfection in 48-well plates with sufficient cells to give ∼50% con-
fluence at the time of transfection. Plasmid DNA was complexed 
with Lipofectamine 2000, as described by the manufacturer (Invitro-
gen, Carlsbad, CA). Cells were transfected with luciferase constructs 
at ∼0.2 μg of plasmid DNA per 100,000 cells. Transfection efficiency 
under experimental conditions was monitored in separate experi-
ments by cotransfection with 1) a plasmid expressing firefly luciferase 
plus 2) sufficient plasmid expressing Renilla sea pansy luciferase 
(pRL-SV40; Promega, Madison, WI) to give 2–10% of the firefly re-
porter activity. Correction for Renilla activity did not change the 
variation in the firefly data (Supplemental Table S2). Cells were lysed 
after 18–24 h with Cell Culture Lysis Reagent or Passive Lysis Buffer 
(for Renilla) (Promega) and the lysate frozen at −80°C. The luciferase 
activity in the lysate of ∼20,000 cells (20 μl of a 100-μl lysate of a well 
from a 48-well plate) was determined following addition of luciferin 
substrate (Promega) in LMax (Molecular Dynamics, Sunnyvale, CA) 
or Centro LB 960 (Berthold, Oak Ridge, TN) luminometers. Transfec-
tions were performed in triplicate or quadruplicate. The effect of 
AUF1-binding proteins on VEGF-3′ UTR–dependent luciferase pro-
duction was measured by cotransfecting the AUF1 expression plas-
mids (pcDNA-3.1 is the parent vector) together with luciferase re-
porter plasmids. Reporter activity of cotransfected cells is expressed 
relative to the activity of cells transfected with the empty expression 
plasmid, pcDNA-3.1. To determine whether experimental condi-
tions affected the luciferase reporter, parallel wells were transfected 
with the parent luciferase (3.1-luciferase) instead of the VEGF-3′ 
UTR-luciferase. Experimental conditions did not affect the parent 
luciferase (Supplemental Table S1). All experiments were performed 
two or more times.
For transfection studies of BMDMs, cells were suspended with 
trypsin and counted. Cells were incubated with plasmid DNA and 
electroporated using the Amaxa BMDM buffer, as described by the 
manufacturer (Lonza, Basel, Switzerland). Cells were lysed after 24 h 
and luciferase activity measured in 20 μl of cell lysate.
Immunoblotting
Total protein was measured using either Bradford assay (Bio-Rad, 
Hercules, CA) or bicinchoninic acid (Pierce, Thermo Fisher Scientific, 
Rockford, IL). Equal amounts of protein were separated on Invitro-
gen 4–12% Tris-glycine gels and transferred to polyvinylidene fluo-
ride membranes using the I-blot system (Invitrogen) or by wet trans-
fer (Bio-Rad). In some experiments, all four AUF1 isoforms could be 
resolved using gradient gels and the I-Blot transfer system. Precision 
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were created by PCR and cloned into pcDNA-3.1-V5-His. The 
AUF1-Ex6+8 construct includes the region encoded by exons 6 and 
8 (aa 234–287), and AUF1-QRGG includes the region from the 
polyglutamine motif to the C-terminus (aa 244–287). The sense 
primer introduced an initiating methionine codon. Amino acid 
numbering is based on human AUF1-p37, GenBank reference file 
NM_001003810. All AUF1 C-terminal fragments were cloned using 
the pcDNA-3.1-V5-His cloning construct (Invitrogen). DNA 
sequencing on both strands verified the integrity of all constructs.
Luciferase constructs. The parental (3.1-luciferase) and full-length 
VEGF-3′ UTR-luciferase (mouse VEGF-3′ UTR, nt-209-1747, GenBank 
AF317892) expression plasmids were constructed as previously 
described (Du et al., 2006). Briefly, the luciferase gene from pGL3 
(Promega) was cloned into pcDNA-3.1. Then the VEGF 3′ UTR was 
cloned into the 3′ UTR of the luciferase gene.
Statistical analysis
Experimental conditions were analyzed in triplicate or quadrupli-
cate. Results are shown as mean and SD. Significant differences 
in results were determined by t test using GraphPad Prism 
(GraphPad Software, La Jolla, CA), and p < 0.05 was considered 
significant.
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